IPM Chirana Announces High-Profile Leadership Team to Drive Global Production and Launch of Critical Care Ventilator

Share Article

IPM Chirana, a new joint venture formed to rapidly accelerate the production of vital ICU ventilators to combat the effects of COVID-19, has appointed Bud Reeves as Chief Executive Officer and Mike Gentile as Vice President of Medical Affairs. The high-profile team will lead the international production of the Chirana Aura V ventilator, an advanced critical care ventilation system, as it launches to the global market.

“There is clear international demand for ICU ventilators, like the Chirana Aura V, and I look forward to working alongside our partners across the globe to lead the company’s efforts in making the product available,” said Reeves.

IPM Chirana, a new joint venture formed to rapidly accelerate the production of vital ICU ventilators to combat the effects of COVID-19, has appointed Bud Reeves as Chief Executive Officer and Mike Gentile as Vice President of Medical Affairs. The high-profile team will lead the international production of the Chirana Aura V ventilator, an advanced critical care ventilation system, as it launches to the global market.

In one of the most significant bids to aid the global fight against the COVID-19 pandemic, IPM Chirana was formed as a strategic partnership between Europe’s leading InfraTech asset manager, IPM Group, Chirana Medical, Ximedica and NDA Partners to rapidly accelerate global production of Chirana Aura V critical care ventilators.

As IPM Chirana’s new Chief Executive Officer, Bud Reeves will lead efforts to address the shortage of critical care ventilators by ensuring that the Aura V ventilator will be made available internationally. With over 20 years of experience in leadership and sales experience in the medical respiratory industry, Reeves will first support manufacturing efforts in the Americas, as the company looks to expand global production of the Aura V by approximately 5,000 ventilators per annum. Reeves previously served as Director of Sales and Strategic Business Channels at Phillips Healthcare, prior to which he served as Director of Sales, Corporate and Strategic Accounts at Respironics, overseeing all GPO, IDN and distribution management.

“The opportunity to lead the global expansion of IPM Chirana at this critical time is very exciting,” said Reeves. “There is clear international demand for ICU ventilators, like the Chirana Aura V, and I look forward to working alongside our partners across the globe to lead the company’s efforts in making the product available.”

Mike Gentile joins IPM Chirana as Vice President of Medical Affairs, following his role as Vice President of Medical Affairs at VERO Biotech, where he successfully helped launch the first tankless inhaled nitric oxide system at the US-based medical technology company. Gentile previously held the position of Associate in Research at Duke University, one of the world’s leading medical universities, from 2003-2018, where he formulated and guided research, teaching and testing of mechanical ventilation technology and strategies.

“I’m very pleased to join IPM Chirana at this immensely important time for the medical technology industry,” said Gentile. “As leaders in the field of ventilation, IPM Chirana has huge potential to become critically important to the global production of ICU ventilators, and I look forward to working closely with the team to ensure the company can realize its global ambition.”

Reeves will take up his position from IPM Chirana’s office in North Carolina from which he will look to establish a team to drive regulatory approvals and a best-in-class sales team. Gentile will also be based in the North Carolina office and will support the regulatory process for the Aura V ventilator, clinical studies, marketing and further product development.

“We are delighted to welcome both Bud and Mike to the leadership team at IPM Chirana,” added Peter Gajdos, IPM Chirana Executive Chairman and Head of Venture Capital at IPM Group. “Their combined experience, expertise and dedication to the industry will be invaluable as we launch in the global market. We are very confident that their track record of success in building strong teams and delivering consistently high performing results will help rapidly grow the company in the USA and globally.”

About IPM Chirana
IPM Chirana is an international joint venture comprising of Chirana Medical (medical technology), IPM Group (finance and strategy), Ximedica (design and contract manufacturing) and NDA Partners (regulatory advisory).
https://www.ipmllp.com/case-study/ipm-chirana/

About IPM Group
IPM Group (“IPM”) is an asset and wealth management company that currently holds more than one billion US dollars in assets under management. IPM was established in London in 2014 and has global presence with offices in London, Bratislava, Seoul, San Francisco and Hong Kong.   

The IPM’s portfolio companies are positioned to solve some of the world’s pressing issues across sectors including energy, mobility and AI enabled critical infrastructure. The dynamic and disruptive approach of the company has seen it become responsible for many ‘first of their kind’ transactions across the globe, in the process, seeding Silicon Valley expertise in the heart of the Danube Valley. The company has the potential to support Europe’s bid for technological and supply chain sovereignty in its areas of activity.
http://www.ipmllp.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bud Reeves
Visit website